MacroGenics, Inc.

we will begin the Macrogenics 2021 Second Quarter Corporate Progress and Financial Results Conference Call in just a moment. All participants are in a listen-only mode at the moment, and we will conduct a question-and-answer session at the conclusion of the call. At this point, I will turn the call over to Chris James, Vice President of Investor Relations and Corporate Communications of Macrogenics.

Thank you, Operator. Thank you, Operator. Good afternoon and welcome to Macrogenics conference call to discuss our second quarter 2021 financial and operational results. For anyone who has not had the chance to review these results, we issued a press release this afternoon outlining today's announcements, which is available under the investors tab on our website at macrogenics.com. You may also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately two hours after the call is completed. I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our annual, quarterly, and current reports filed with the SEC. In addition, any forward-looking statement represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change, except to the extent required by applicable law. And now, I'd like to turn the call over to Dr. Scott Koenig, President and Chief Executive Officer of Maprogenics.

Thank you, Chris. I'd like to welcome everyone participating via conference call and webcast today. For those who have not yet met Chris James, he recently joined Microgenics as our VP of Investor Relations and Corporate Communications. We are delighted to have him on board. This afternoon, I will provide key highlights from our clinical programs. But before I do so, let me first turn the call to Jim Carrolls. our Chief Financial Officer, who will review our financial results for the second quarter.